Phase III

Sumitovant Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones

Lead Product(s): Vibegron,Tolterodine

Therapeutic Area: Urology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting

Lead Product(s): Vibegron

Therapeutic Area: Urology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

52-week post hoc analysis shows Vibegron patients had statistically significant, sustained reduction in UUI and total incontinence episodes compared to active control.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results

Lead Product(s): Vibegron

Therapeutic Area: Urology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2020

Details:

The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Sumitovant Biopharma

Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones

Urovant Sciences

Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting

Urovant Sciences

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results